Author

Peggy Krozely

Observed names: P Krozely, P. Krozely

Institutions: Sarah Cannon, Vanderbilt University Medical Center

Observed institutions: Memorial Sloan Kettering Cancer Center, Vanderbilt University, Cornell University, Sarah Cannon, Weill Cornell Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

OpenAlex ID: A5072065263

Pilot Trial of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib Plus Carboplatin and Paclitaxel in Patients With Stage IIIB or IV Non–Small-Cell Lung Cancer

2003 · Vincent A. Miller, David H. Johnson, et al. · Journal of Clinical Oncology · 63

A Phase II trial of 6-Hydroxymethylacylfulvene (MGI-114, Irofulven) in Patients with Advanced Non-Small Cell Cancer Previously Treated with Chemotherapy

2001 · Jonathan E. Dowell, David H. Johnson, et al. · Investigational New Drugs · 20

A multicenter phase II study of erlotinib and bevacizumab in patients with metastatic melanoma

2007 · K. Wyman, D. Spigel, et al. · Journal of Clinical Oncology · 14

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Evolving Role in the Treatment of Solid Tumors

2004 · Peggy Krozely · Clinical journal of oncology nursing · 13

Phase II study of erlotinib given daily for patients with metastatic melanoma (MM)

2006 · K. Wyman, M. Kelley, et al. · Journal of Clinical Oncology · 7

Objective responses from adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioalveolar cell lung carcinoma (BAC)

2000 · D.P Carbone, S Adak, et al. · Lung Cancer · 2

Works count: 6

Citation count: 119

H-index: 5

I10-index: 4